300677 Intco Medical Technology
- 27.14
- -0.25-0.91%
Intco Medical Technology News
Intco Medical Technology (300677.SZ): The cumulative repurchased 0.3033 million shares.
Intco Medical Technology (300677.SZ) announced that, as of October 31, 2024, the company has repurchased a total of 303,300 shares through a share repurchase dedicated securities account via centralized auction trading, accounting for 0.0469% of the total share capital (based on the total share capital of 646,185,763 shares as of October 31, 2024). The highest fill price was 21.62 yuan/share, the lowest fill price was 20.99 yuan/share, and the total fill amount was RMB 6,467,649.00 (excluding trading expenses).
British Healthcare: Report for the third quarter of 2024
Express News | Intco Medical Technology Says Q3 Net Profit up 166.5% Y/Y
Individual Investors Invested in Intco Medical Technology Co., Ltd. (SZSE:300677) up 5.9% Last Week, Insiders Too Were Rewarded
Intco Medical Technology Co., Ltd.'s (SZSE:300677) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Selected Announcement: Oulai New Materials: plans to invest no less than 2.59 billion yuan to build the Oulai New Materials Mingyue Lake Industrial Park project; Intco Medical Technology: plans to repurchase company shares worth 80 million to 0.12 billion
Beijing Tianyishangjia New Material Corp.: Tianrendahe intends to cooperate with Xinghe Power in the research and development and manufacturing of solid and liquid launch vehicle related components.
GLE.FE Announcement Selection | Oulai New Materials: Intends to invest no less than 2.59 billion yuan to build Oulai New Materials Mingyue Lake Industrial Park project; Intco Medical Technology: Intends to repurchase company shares worth 80 million yuan t
[Company Business Data] Yunda Holding (002120.SZ): In August, the express service business income was 3.917 billion yuan, a year-on-year increase of 11.41%. sto express co.,ltd. (002468.SZ): In August, the express service business income was 3.873 billion yuan, a year-on-year increase of 21.5%. YTO Express Group (600233.SH): In August, the express product income was 4.908 billion yuan, a year-on-year increase of 20.67%. guilin layn natural ingredients corp. (002166.SZ): Net income is expected to increase by 100%-150% in the first three quarters. [Contract Projects] Oulei New Materials (688530.SH): Intends to be no less than 2.59 billion.
intco medical technology (300677.SZ): plans to repurchase company shares worth 80 million to 0.12 billion yuan.
On September 19, Intco Medical Technology (300677.SZ) announced that it plans to repurchase a total amount of shares not less than RMB 80 million and not exceeding RMB 120 million, with a maximum repurchase price of RMB 26.66 per share, for the purpose of implementing employee stock ownership plans and/or stock-based incentives.
The threat of additional tariffs looms high, intco medical technology's stock price drops by 20%, What are the prospects for its North American layout?
①Today, Intco Medical Technology's stock fell 20 centimeters in the intraday trading session. An employee from the securities department of Intco Medical Technology stated, 'This is because the United States announced the impact of increasing tariffs on some Chinese commodities under Section 301.' ②The employee said that the proportion of the U.S. market in the company's revenue is about 35%, which may pose challenges to the company's performance in the short term. However, the overall potential of the U.S. market is still significant, and the company still plans to increase its efforts to expand into the North American market.
Solid Earnings May Not Tell The Whole Story For Intco Medical Technology (SZSE:300677)
Intco Medical Technology (SZSE:300677) May Have Issues Allocating Its Capital
British Healthcare: 2024 Semi-Annual Report Summary
British Healthcare: 2024 Semi-Annual Report
Building a global marketing network, Intco Medical Technology (300677.SZ) achieved a significant increase of 100.24% in net profit to 587 million yuan in the first half of the year, and plans to distribute 0.5 yuan per 10 shares.
Intco Medical Technology (300677.SZ) released its semi-annual report for 2024, during which the company achieved revenue of 4...
Intco Medical Technology (300677.SZ): Net income in the first half of the year increased by 100.24% to 0.587 billion yuan. It plans to distribute a dividend of 0.5 yuan per share.
Glory Medical (300677.SZ) announced its interim report for the first half of 2024, with a reported revenue of 4.512 billion yuan, a year-on-year increase of 36.94%; net income attributable to the shareholders of the listed company was 0.587 billion yuan, an increase of 100.24% year-on-year; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.487 billion yuan, an increase of 185.23% year-on-year; basic earnings per share was 0.90 yuan; it is proposed to distribute a cash dividend of 0.5 yuan (tax included) to all shareholders for every 10 shares.
These 4 Measures Indicate That Intco Medical Technology (SZSE:300677) Is Using Debt Reasonably Well
The Market Doesn't Like What It Sees From Intco Medical Technology Co., Ltd.'s (SZSE:300677) Earnings Yet
Intco Medical Technology (300677.SZ) mainly uses clean coal, which further reduces the company's energy consumption costs compared to competitors who use henry hub natural gas, steam, and other energy sources.
On July 24th, InTco Medical Technology (300677.SZ) expressed on the investor interaction platform that, as a global leader in the disposable glove industry, the company has continuously strengthened its advantages upstream and downstream in the industry chain, and continuously carried out cost-saving and efficiency-increasing work in all aspects. After the first quarter report, cost advantages are highlighted. First, based on years of equipment integration experience and continuous improvement and innovation, the company has built the third generation production line through independent research and development. On the basis of ensuring product quality, it has industry-leading production line speed, lower energy consumption, and lower weight control level. Second, in terms of energy, the company mainly uses clean energy.
Intco Medical Technology (300677.SZ): The company's overseas orders are mainly in the form of FOB orders, and the marine transportation costs are borne by the customer.
Intco Medical Technology (300677.SZ) stated on the investor interaction platform on July 24th that its overseas orders are mainly in the form of FOB orders, and marine transportation costs are borne by the customers. At the same time, the company has signed a long-term stable strategic cooperation agreement with top marine transportation groups, and the company's support department actively utilizes company resources to help customers find suitable shipping solutions, fully ensuring high-level service quality for customers.
Since the beginning of this year, Intco Medical Technology (300677.SZ) has maintained full production and sales with a lead time of 2-3 months for orders.
Intco Medical Technology (300677.SZ) said on the investor interaction platform on July 24 that from the second half of 2023, the inventory backlog in the downstream of the industry has entered the final digestion stage. The effect of clearing high-cost and outdated production capacity has become apparent, and the concentration of the industry's supply side has increased. The overall production capacity utilization rate of the industry's leading enterprises has generally increased, and the supply-demand relationship has gradually returned to a balanced trend. Since the beginning of this year, the company has maintained full production and sales, with a lead time of 2-3 months and a slight increase in the price of disposable gloves compared to the previous period.
Analysis
Price Target
No Data
No Data